JAK inhibitors

target reach ladder climb meet win beat competition

Soterios looks to ph. 3 after win for alopecia areata cream

Soterios is eyeing phase 3 after a 1% dose of its alopecia areata cream improved severity of the condition, hitting the main goal of a mid-stage test.

James Waldron May 30, 2024 8:14am

An arrow incrementally going up stairs before pointing straight up Blue background

Incyte's oral Dupixent rival hits in midphase skin disease trial

Mar 11, 2024 7:16am

How Takeda beat the rest of the industry to snag Nimbus' TYK2

Jan 11, 2024 10:30am

Aclaris lays off 46%, resurrects zunsemetinib for cancer

Dec 20, 2023 6:09am

ASH: AZ spinout Dizal explores FDA path, US partner for PTCL med

Dec 11, 2023 4:30am

Lynk’s JAK1 inhibitor improves severity, itching in eczema study

Aug 9, 2023 12:35pm